181 related articles for article (PubMed ID: 37454141)
21. Predictive Value of BRAF
Song JY; Sun SR; Dong F; Huang T; Wu B; Zhou J
Curr Med Sci; 2018 Oct; 38(5):785-797. PubMed ID: 30341513
[TBL] [Abstract][Full Text] [Related]
22. Risk and Prognostic Factors for BRAF
Wei X; Wang X; Xiong J; Li C; Liao Y; Zhu Y; Mao J
Biomed Res Int; 2022; 2022():9959649. PubMed ID: 35647194
[TBL] [Abstract][Full Text] [Related]
23. BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.
Kurtulmus N; Duren M; Ince U; Cengiz Yakicier M; Peker O; Aydın O; Altiok E; Giray S; Azizlerli H
Endocrine; 2012 Oct; 42(2):404-10. PubMed ID: 22426956
[TBL] [Abstract][Full Text] [Related]
24. Metastatic thyroid carcinoma without identifiable primary tumor within the thyroid gland: a retrospective study of a rare phenomenon.
Xu B; Scognamiglio T; Cohen PR; Prasad ML; Hasanovic A; Tuttle RM; Katabi N; Ghossein RA
Hum Pathol; 2017 Jul; 65():133-139. PubMed ID: 28552827
[TBL] [Abstract][Full Text] [Related]
25. Progression of Papillary Thyroid Carcinoma to Anaplastic Carcinoma in Metastatic Lymph Nodes: Solid/Insular Growth and Hobnail Cell Change in Lymph Nodes Are Predictors of Subsequent Anaplastic Transformation.
Odate T; Oishi N; Kawai M; Tahara I; Mochizuki K; Akaishi J; Ito K; Katoh R; Kondo T
Endocr Pathol; 2021 Sep; 32(3):347-356. PubMed ID: 33761111
[TBL] [Abstract][Full Text] [Related]
26. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
[TBL] [Abstract][Full Text] [Related]
27. A prediction model incorporating the BRAF
Liu S; Liu C; Zhao L; Wang K; Li S; Tian Y; Jiao B; Gui Z; Yu T; Zhang L
Eur J Surg Oncol; 2021 Nov; 47(11):2774-2780. PubMed ID: 34483032
[TBL] [Abstract][Full Text] [Related]
28. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.
Xing M; Alzahrani AS; Carson KA; Viola D; Elisei R; Bendlova B; Yip L; Mian C; Vianello F; Tuttle RM; Robenshtok E; Fagin JA; Puxeddu E; Fugazzola L; Czarniecka A; Jarzab B; O'Neill CJ; Sywak MS; Lam AK; Riesco-Eizaguirre G; Santisteban P; Nakayama H; Tufano RP; Pai SI; Zeiger MA; Westra WH; Clark DP; Clifton-Bligh R; Sidransky D; Ladenson PW; Sykorova V
JAMA; 2013 Apr; 309(14):1493-501. PubMed ID: 23571588
[TBL] [Abstract][Full Text] [Related]
29. Significance of multifocality in papillary thyroid carcinoma.
Feng JW; Qu Z; Qin AC; Pan H; Ye J; Jiang Y
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1820-1828. PubMed ID: 32732090
[TBL] [Abstract][Full Text] [Related]
30. [Correlation between Ultrasound-guided Fine-needle Aspiration Combined with BRAF
Zhang Y; Luo YK; Zhang Y; Zhang MB; Guang Y; Xie F; Jiang B; Tang J
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2019 Aug; 41(4):517-523. PubMed ID: 31484615
[TBL] [Abstract][Full Text] [Related]
31. LIMD2 Is Overexpressed in BRAF V600E-Positive Papillary Thyroid Carcinomas and Matched Lymph Node Metastases.
Pinheiro Dos Santos MJC; Bastos AU; da Costa VR; Delcelo R; Lindsey SC; Colozza-Gama GA; Peng H; Rauscher FJ; Oler G; Cerutti JM
Endocr Pathol; 2018 Sep; 29(3):222-230. PubMed ID: 29560564
[TBL] [Abstract][Full Text] [Related]
32. [Study on the correlation between BRAF(V600E) mutation and lymphatic metastases in papillary thyroid cancer staged preoperativelv as N0].
Gao Q; Zhang W; Wang N; Duan H; Zhou Y; Zhang W; Zhao D
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Dec; 29(23):2048-52. PubMed ID: 27101676
[TBL] [Abstract][Full Text] [Related]
33. Associations of the BRAF V600E Mutation and PAQR3 Protein Expression with Papillary Thyroid Carcinoma Clinicopathological Features.
Gao J; Ma XP; Deng FS; Jiang L; Jia WD; Li M
Pathol Oncol Res; 2020 Jul; 26(3):1833-1841. PubMed ID: 31758408
[TBL] [Abstract][Full Text] [Related]
34. Association between BRAF V600E mutation and regional lymph node metastasis in papillary thyroid carcinoma.
Lu J; Gao J; Zhang J; Sun J; Wu H; Shi X; Teng L; Liang Z
Int J Clin Exp Pathol; 2015; 8(1):793-9. PubMed ID: 25755776
[TBL] [Abstract][Full Text] [Related]
35. BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates.
Al-Salam S; Sharma C; Afandi B; Al Dahmani K; Al-Zahrani AS; Al Shamsi A; Al Kaabi J
PLoS One; 2020; 15(4):e0231341. PubMed ID: 32315324
[TBL] [Abstract][Full Text] [Related]
36. Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis with ARMS PCR.
Zhang J; Yang Y; Zhao J; Shi L; Xu Y; Yu K; Guo C
Pathol Res Pract; 2019 Apr; 215(4):761-765. PubMed ID: 30819583
[TBL] [Abstract][Full Text] [Related]
37. [Association between BRAF V600E mutation and central lymph node metastasis in patients with papillary thyroid carcinoma].
Shi C; Qin H; Ding C; Sun Y; Lyu Y; Shi T
Zhonghua Zhong Liu Za Zhi; 2015 Feb; 37(2):123-7. PubMed ID: 25975689
[TBL] [Abstract][Full Text] [Related]
38. Notch1 receptor as a marker of lymph node metastases in papillary thyroid cancer.
Park HS; Jung CK; Lee SH; Chae BJ; Lim DJ; Park WC; Song BJ; Kim JS; Jung SS; Bae JS
Cancer Sci; 2012 Feb; 103(2):305-9. PubMed ID: 22118425
[TBL] [Abstract][Full Text] [Related]
39. False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma.
Paek SH; Kim BS; Kang KH; Kim HS
World J Surg Oncol; 2017 Nov; 15(1):202. PubMed ID: 29132392
[TBL] [Abstract][Full Text] [Related]
40. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer.
Kim SJ; Lee KE; Myong JP; Park JH; Jeon YK; Min HS; Park SY; Jung KC; Koo do H; Youn YK
World J Surg; 2012 Feb; 36(2):310-7. PubMed ID: 22190222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
